Search research articles
Contact Us
Filters
Showing results (1-10 of 42) with videos related to
Page
of 5
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
April 20, 2013
Targeting bone physiology for the treatment of metastatic prostate cancer
Karen A Autio, Michael J Morris
Current Treatment Options in Oncology
|
April 25, 2012
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer
Karen A Autio, Howard I Scher, Michael J Morris
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2019
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
Karen A Autio, Valentina Boni, Rachel W Humphrey, et al.
Nature Reviews. Clinical Oncology
|
May 21, 2014
High-risk prostate cancer-classification and therapy
Albert J Chang, Karen A Autio, Mack Roach, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|
November 6, 2004
Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia
Maria G Vogiatzi, Karen A Autio, Robert Schneider, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
April 29, 2020
Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
Daniel Vargas P de Almeida, Lawrence Fong, Matthew B Rettig, et al.
Endocrine-Related Cancer
|
February 28, 2015
Targeting the androgen receptor in prostate and breast cancer: several new agents in development
Tracy Proverbs-Singh, Jarett L Feldman, Michael J Morris, et al.
Annals of the New York Academy of Sciences
|
December 13, 2005
Low bone mineral density in adolescents with beta-thalassemia
Maria G Vogiatzi, Karen A Autio, Jeffrey E Mait, et al.
Seminars in Oncology
|
June 29, 2013
Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?
Michael J Morris, Karen A Autio, Ethan M Basch, et al.
Investigational New Drugs
|
September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes
Karen A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 42) with videos related to
Sort By:
Page
of 5
Clinical Advances in Hematology & Oncology : H&O
|
April 20, 2013
Targeting bone physiology for the treatment of metastatic prostate cancer
Karen A Autio, Michael J Morris
Current Treatment Options in Oncology
|
April 25, 2012
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer
Karen A Autio, Howard I Scher, Michael J Morris
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2019
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
Karen A Autio, Valentina Boni, Rachel W Humphrey, et al.
Nature Reviews. Clinical Oncology
|
May 21, 2014
High-risk prostate cancer-classification and therapy
Albert J Chang, Karen A Autio, Mack Roach, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|
November 6, 2004
Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia
Maria G Vogiatzi, Karen A Autio, Robert Schneider, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
April 29, 2020
Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
Daniel Vargas P de Almeida, Lawrence Fong, Matthew B Rettig, et al.
Endocrine-Related Cancer
|
February 28, 2015
Targeting the androgen receptor in prostate and breast cancer: several new agents in development
Tracy Proverbs-Singh, Jarett L Feldman, Michael J Morris, et al.
Annals of the New York Academy of Sciences
|
December 13, 2005
Low bone mineral density in adolescents with beta-thalassemia
Maria G Vogiatzi, Karen A Autio, Jeffrey E Mait, et al.
Seminars in Oncology
|
June 29, 2013
Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?
Michael J Morris, Karen A Autio, Ethan M Basch, et al.
Investigational New Drugs
|
September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes
Karen A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.
Page
of 5